BRPI0415622A - linhas de células aviárias importalizadas para produção de vìrus - Google Patents

linhas de células aviárias importalizadas para produção de vìrus

Info

Publication number
BRPI0415622A
BRPI0415622A BRPI0415622-6A BRPI0415622A BRPI0415622A BR PI0415622 A BRPI0415622 A BR PI0415622A BR PI0415622 A BRPI0415622 A BR PI0415622A BR PI0415622 A BRPI0415622 A BR PI0415622A
Authority
BR
Brazil
Prior art keywords
cell lines
virus production
imported
immortalized
avian cell
Prior art date
Application number
BRPI0415622-6A
Other languages
English (en)
Inventor
Volker Sandig
Ingo Jordan
Original Assignee
Probiogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34400514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Probiogen Ag filed Critical Probiogen Ag
Publication of BRPI0415622A publication Critical patent/BRPI0415622A/pt
Publication of BRPI0415622B1 publication Critical patent/BRPI0415622B1/pt
Publication of BRPI0415622B8 publication Critical patent/BRPI0415622B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10251—Methods of production or purification of viral material
    • C12N2710/10252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"LINHAS DE CéLULAS AVIáRIAS IMORTALIZADAS PARA PRODUçãO DE VìRUS". A presente invenção refere-se a uma linha de célula de aves imortalizada, adequada para produtos biológicos ou vírus para vacinação. Particularmente, as linhas de células são derivadas de células primárias, que são transformadas com pelo menos dois genes virais ou celulares, um dos quais ocasiona o progresso do ciclocelular, enquanto o outro, interfere com os mecanismos protetores intrínsecos da célula, induzidos por replicação desregulada. A invenção, além disso, refere-se à produção de tais linhas de células imortalizadas e a seu emprego em produtos biológicos ou vírus para vacinação.
BRPI0415622A 2003-11-03 2004-11-03 uso de uma linhagem de células de somito ou retina de pato imortalizada, bem como métodos para preparar uma linhagem de células de somito ou retina de pato imortalizada, e para produção de vírus BRPI0415622B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03025158.1 2003-11-03
EP03025158A EP1528101A1 (en) 2003-11-03 2003-11-03 Immortalized avian cell lines for virus production
PCT/EP2004/052789 WO2005042728A2 (en) 2003-11-03 2004-11-03 Immortalized avian cell lines for virus production

Publications (3)

Publication Number Publication Date
BRPI0415622A true BRPI0415622A (pt) 2006-12-12
BRPI0415622B1 BRPI0415622B1 (pt) 2021-01-26
BRPI0415622B8 BRPI0415622B8 (pt) 2021-05-25

Family

ID=34400514

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415622A BRPI0415622B8 (pt) 2003-11-03 2004-11-03 uso de uma linhagem de células de somito ou retina de pato imortalizada, bem como métodos para preparar uma linhagem de células de somito ou retina de pato imortalizada, e para produção de vírus

Country Status (18)

Country Link
US (2) US8940534B2 (pt)
EP (4) EP1528101A1 (pt)
JP (1) JP4658953B2 (pt)
KR (1) KR101027755B1 (pt)
CN (1) CN1934243B (pt)
AT (2) ATE398672T1 (pt)
AU (1) AU2004285089B2 (pt)
BR (1) BRPI0415622B8 (pt)
CA (1) CA2544462C (pt)
CY (1) CY1110272T1 (pt)
DE (2) DE602004025996D1 (pt)
DK (2) DK1685243T3 (pt)
ES (1) ES2309578T3 (pt)
PL (1) PL1685243T3 (pt)
PT (1) PT1685243E (pt)
RU (1) RU2359999C2 (pt)
SI (1) SI1685243T1 (pt)
WO (1) WO2005042728A2 (pt)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432101B2 (en) * 2003-07-22 2008-10-07 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
DK2179744T3 (da) 2004-09-09 2011-01-31 Novartis Vaccines & Diagnostic Nedsættelse af potentielle iatrogene risici forbundet med influenzavacciner
ATE494906T1 (de) 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
WO2007052155A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
EP1783210A1 (en) 2005-11-08 2007-05-09 ProBioGen AG Productivity augmenting protein factors, novel cell lines and uses thereof
DK2478916T3 (da) 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
ES2536401T3 (es) 2006-09-11 2015-05-25 Novartis Ag Fabricación de vacunas contra virus de la gripe sin usar huevos
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
US20100183671A1 (en) 2007-06-27 2010-07-22 Novartis Vaccines & Diagnostics GmbH & Co., KG Low-additive influenza vaccines
JP5421250B2 (ja) * 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム トリ不死化細胞株
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2710480A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
CA2715719C (en) * 2008-02-25 2019-08-06 Baxter International Inc. Method for producing continuous cell lines
EP2098590A1 (en) 2008-03-04 2009-09-09 ProBioGen AG Cell line from Rousettus as host cell for pathogen amplification
CA2718058A1 (en) * 2008-03-04 2009-09-11 Probiogen Ag Cell line from rousettus as host cell for pathogen amplification
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
US20110229969A1 (en) * 2008-06-25 2011-09-22 Volker Sandig Cell Line for Propagation of Highly Attenuated AlphaViruses
EP2199385A1 (en) 2008-12-16 2010-06-23 ProBioGen AG Specific and persistent activation of heat shock response in cell lines using a viral factor
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
WO2010089339A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
CN105727281A (zh) 2009-02-10 2016-07-06 诺华股份有限公司 具有减少量的角鲨烯的流感疫苗
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
BE1019643A3 (fr) 2009-04-27 2012-09-04 Novartis Ag Vaccins de protection contre la grippe.
EP3988115A3 (en) 2009-07-15 2022-08-17 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011040527A1 (ja) * 2009-09-30 2011-04-07 国立大学法人帯広畜産大学 α-ガラクトースエピトープを発現するトランスジェニック鳥類、ウイルス及びワクチン
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
AU2011225748A1 (en) 2010-03-08 2012-09-13 Novartis Ag Methods of testing for intracellular pathogens
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
US20130203151A1 (en) 2010-04-26 2013-08-08 Scott Balsitis Production of alphavirus replicon particles in packaging cells
ES2562818T3 (es) 2010-05-03 2016-03-08 Glaxosmithkline Biologicals S.A. Procedimiento de inactivación del virus de la gripe
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
WO2011151726A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
BR112012030619A2 (pt) 2010-06-01 2019-09-24 Novartis Ag concentração de antígenos de vacina influenza sem liofilização.
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
CA2814704C (en) * 2010-11-02 2020-04-07 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Methods and vectors for cell immortalisation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
ES2727836T3 (es) 2011-01-26 2019-10-21 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
EP3275892B1 (en) 2011-05-13 2020-01-08 GlaxoSmithKline Biologicals S.A. Pre-fusion rsv f antigens
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
KR20150085843A (ko) 2012-11-20 2015-07-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Rsv f 융합전 삼합체
CN103060376A (zh) * 2012-12-11 2013-04-24 上海实验动物研究中心 一种禽腺病毒转移载体及其制备方法
RU2015132962A (ru) 2013-01-10 2017-02-14 Новартис Аг Иммуногенные композиции на основе вируса гриппа и их применение
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
BR112016004136B1 (pt) 2013-08-30 2023-04-11 Km Biologics Co., Ltd. Métodos para produzir um vírus em uma cultura celular e para a preparação de uma vacina
CN104726409B (zh) * 2013-12-19 2017-12-29 普莱柯生物工程股份有限公司 一种永生化的鸭胚肝细胞系的制备方法和应用
JP2017512839A (ja) * 2014-04-02 2017-05-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用タンパク質の生産
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
PL3227433T3 (pl) * 2014-12-04 2019-01-31 Intervet International B.V. Unieśmiertelnione fibroblasty zarodków kurzych
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
EP3234113B1 (en) 2014-12-16 2019-01-23 GlaxoSmithKline Biologicals S.A. A method for a large scale virus purification
SG11201704690TA (en) 2014-12-17 2017-07-28 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease
PT3233129T (pt) 2014-12-17 2020-04-15 Fundacion Para La Investig Medica Aplicada Construções de ácido nucleico e vetores de terapia génica para utilização no tratamento de doença de wilson e outras condições
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
EP3320343B1 (en) 2015-07-07 2020-09-02 Seqirus UK Limited Method for quantifying immunogenic hemagglutinin
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN107012122A (zh) * 2016-12-12 2017-08-04 江苏省农业科学院 一种永生化鸡胚胎肝细胞系及其制备方法和用途
EP3562946B1 (en) 2016-12-28 2021-11-24 Transgene SA Oncolytic viruses and therapeutic molecules
WO2018176103A1 (en) 2017-03-30 2018-10-04 The University Of Queensland "chimeric molecules and uses thereof"
AU2018287159A1 (en) 2017-06-21 2020-01-16 Transgene Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
US12076369B2 (en) 2017-09-01 2024-09-03 The Frances Crick Institute Limited Immunoregulatory molecules and uses therefor
AU2018359420A1 (en) 2017-10-31 2020-06-04 Kalivir Immunotherapeutics, Inc. Platform oncolytic vector for systemic delivery
WO2019092002A1 (en) 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
EP3794127A1 (en) 2018-05-14 2021-03-24 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
US12053518B2 (en) 2018-07-13 2024-08-06 Valneva Se Method for rescuing and producing a virus in avian cells
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110396496B (zh) * 2018-09-30 2023-06-20 湖北省农业科学院畜牧兽医研究所 一种鸭小肠上皮细胞的培养方法及应用
ES2948378T3 (es) 2018-10-12 2023-09-11 Vivet Therapeutics Transgén con codones optimizados para el tratamiento de la colestasis intrahepática familiar progresiva de tipo 3 (PFIC3)
CN109321516A (zh) * 2018-11-07 2019-02-12 贵州大学 一种鸭原代肝细胞分离及培养方法
CN112955186A (zh) 2018-11-07 2021-06-11 维韦特治疗公司 用于治疗进行性家族性肝内胆汁淤积症2型(pfic2)的密码子优化的abcb11转基因
CA3118936A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
CA3120166A1 (en) 2018-11-23 2020-05-28 Valneva Se Food products comprising avian stem cells
SG11202106898VA (en) 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
EP3686276A1 (en) * 2019-01-28 2020-07-29 Freie Universität Berlin Production of viruses in continuously growing epithelial cell lines derived from chicken gut
JP2022544740A (ja) 2019-07-02 2022-10-21 フンダシオン・パラ・ラ・インベスティガシオン・メディカ・アプリカダ ｃＰＬＡ２ｅ誘導剤及びその使用
KR20220035457A (ko) 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
AU2021309007A1 (en) 2020-07-13 2023-02-16 Transgene Treatment of immune depression
AR123168A1 (es) 2020-08-06 2022-11-02 Fundacion Para La Investig Medica Aplicada Partículas virales para uso en el tratamiento de tauopatías tales como enfermedades de alzheimer mediante terapia génica
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
CN116390935A (zh) 2020-10-09 2023-07-04 Ucb生物制药有限责任公司 核酸构建体、病毒载体和病毒颗粒
EP4267197A1 (en) 2020-12-23 2023-11-01 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
AU2022206415A1 (en) 2021-01-10 2023-08-17 Supermeat The Essence Of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
TW202305125A (zh) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
EP4419650A1 (en) 2021-10-18 2024-08-28 Supermeat the Essence of Meat Ltd. Methods for preparing a food ingredient and compositions produced thereby
MX2024005171A (es) 2021-10-28 2024-05-13 UCB Biopharma SRL Constructos de acido nucleico, vectores viricos y particulas viricas.
CN114350601B (zh) * 2021-12-21 2022-12-27 广东省华晟生物技术有限公司 樱桃谷鸭成纤维细胞系及其构建方法与应用
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114908053A (zh) * 2022-04-24 2022-08-16 上海交通大学 孔雀成纤维永生化细胞系的制备方法及其在病毒扩增中的应用
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024038175A1 (en) 2022-08-18 2024-02-22 Transgene Chimeric poxviruses
CN116496992B (zh) * 2023-04-24 2023-12-01 江苏省家禽科学研究所 一种鸡胚成肌永生化细胞及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT833934E (pt) * 1995-06-15 2005-02-28 Crucell Holland Bv Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica
KR970010968A (ko) 1995-08-24 1997-03-27 윤원영 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) * 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
FR2767335B1 (fr) 1997-08-14 2001-09-28 Ct Nat D Etudes Veterinaires E Adenovirus aviaire celo recombinant comme vecteur vaccinant
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
CN1139655C (zh) * 2001-08-23 2004-02-25 北京大学人民医院 一种人卵巢癌永生化细胞株及其建立方法
US7473536B2 (en) 2002-08-07 2009-01-06 Bavarian Nordic A/S Isolated avian cell that expresses Vaccinia virus host range genes
UA85543C2 (ru) 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
US7432101B2 (en) 2003-07-22 2008-10-07 Vivalis Production of poxviruses with adherent or non adherent avian cell lines

Also Published As

Publication number Publication date
CA2544462C (en) 2011-10-25
EP1939281A1 (en) 2008-07-02
EP2192173A1 (en) 2010-06-02
DK1685243T3 (da) 2008-10-20
AU2004285089A1 (en) 2005-05-12
AU2004285089B2 (en) 2009-07-02
ES2309578T3 (es) 2008-12-16
BRPI0415622B1 (pt) 2021-01-26
DK1939281T3 (da) 2010-06-14
ATE460473T1 (de) 2010-03-15
US20080227146A1 (en) 2008-09-18
CA2544462A1 (en) 2005-05-12
CN1934243A (zh) 2007-03-21
WO2005042728A3 (en) 2005-07-07
BRPI0415622B8 (pt) 2021-05-25
US8940534B2 (en) 2015-01-27
DK1939281T4 (da) 2014-08-25
ATE398672T1 (de) 2008-07-15
CN1934243B (zh) 2011-07-06
JP2007510409A (ja) 2007-04-26
PL1685243T3 (pl) 2008-12-31
EP1685243B1 (en) 2008-06-18
EP1528101A1 (en) 2005-05-04
EP1939281B2 (en) 2014-06-04
WO2005042728A2 (en) 2005-05-12
DE602004014526D1 (de) 2008-07-31
US20120288916A1 (en) 2012-11-15
DE602004025996D1 (de) 2010-04-22
CY1110272T1 (el) 2015-01-14
KR101027755B1 (ko) 2011-04-07
KR20060123758A (ko) 2006-12-04
EP1685243A2 (en) 2006-08-02
RU2359999C2 (ru) 2009-06-27
SI1685243T1 (sl) 2008-12-31
EP1939281B1 (en) 2010-03-10
RU2006119447A (ru) 2007-12-20
PT1685243E (pt) 2008-09-24
JP4658953B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
BRPI0415622A (pt) linhas de células aviárias importalizadas para produção de vìrus
Geis et al. Silencing and transcriptional regulation of endogenous retroviruses: an overview
Koyuncu et al. Sirtuins are evolutionarily conserved viral restriction factors
Lin et al. Identification of RNA helicase A as a cellular factor that interacts with influenza A virus NS1 protein and its role in the virus life cycle
Gabriel et al. Adaptive mutations in the H5N1 polymerase complex
Hanssen-Bauer et al. X-ray repair cross complementing protein 1 in base excision repair
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
BR112013010525A2 (pt) tratamento de hbv
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BRPI0412153A (pt) métodos para produzir um anticorpo que reage cruzado com produtos de gene kir2dl múltiplos e que neutraliza a atividade inibidora de tais kirs, e para avaliar a toxicidade de um anticorpo, e, anticorpo, fragmento de anticorpo ou um derivado de anticorpo
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
Liu et al. Epigenetic modification is regulated by the interaction of influenza A virus nonstructural protein 1 with the de novo DNA methyltransferase DNMT3B and subsequent transport to the cytoplasm for K48-linked polyubiquitination
BRPI0921096A8 (pt) Composições e métodos para inibir a expressão dos genes de fator vii
Zhu et al. Zebrafish prmt3 negatively regulates antiviral responses
BR112023010717A2 (pt) Composições e métodos para direcionamento de bcl11a
Tamilvanan et al. High-throughput virtual screening and docking studies of matrix protein vp40 of Ebola virus
Haddad et al. miRNA target prediction might explain the reduced transmission of SARS-CoV-2 in Jordan, Middle East
Juan et al. Evolving imprinting control regions: KRAB zinc fingers hold the key
Elmer et al. Strain-specific epigenetic regulation of endogenous retroviruses: the role of trans-acting modifiers
Yashvardhini et al. Identification and characterization of mutations in the SARS-CoV-2 RNA-dependent RNA polymerase as a promising antiviral therapeutic target
Chen et al. Iridovirus CARD protein inhibits apoptosis through intrinsic and extrinsic pathways
Beltran et al. Functional dissection of the ash2 and ash1 transcriptomes provides insights into the transcriptional basis of wing phenotypes and reveals conserved protein interactions
Aletta et al. Protein arginine methylation in health and disease

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 5/06

Ipc: C12N 15/09 (2006.01), C12N 15/12 (2006.01), C12N 5

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF